Brad Sickler
Illumina
7 Papers
5 Citations
Brad Sickler is an academic researcher from Illumina. The author has contributed to research in topics: Exome & Internal medicine. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +64 more
TL;DR: Integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches, providing a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
658
Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +62 more
152
Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Nicole L. Washington,Karthik Gangavarapu,Mark Zeller,Alexandre Bolze,Elizabeth T. Cirulli,Kelly M. Schiabor Barrett,Brendan B. Larsen,Catelyn Anderson,Simon R. White,Tyler Cassens,Sharoni Jacobs,Geraint Levan,Jason Nguyen,Jimmy M. Ramirez,Charlotte Rivera-Garcia,Efren Sandoval,Xueqing Wang,David T.W. Wong,Emily Spencer,Refugio Robles-Sikisaka,Ezra Kurzban,Laura D. Hughes,Xianding Deng,Candace Wang,Venice Servellita,Holly Valentine,Peter De Hoff,Phoebe Seaver,Shashank Sathe,Kimberly Gietzen,Brad Sickler,Jay Antico,Kelly Hoon,Jingtao Liu,Aaron Harding,Omid Bakhtar,Tracy Basler,Brett Austin,Magnus Isaksson,Phil Febbo,David M. Becker,Marc Laurent,Eric McDonald,Gene W. Yeo,Rob Knight,Louise C. Laurent,Eileen de Feo,Michael Worobey,Charles Y. Chiu,Marc A. Suchard,James T. Lu,William E. Lee,Kristian G. Andersen,Kristian G. Andersen +53 more
TL;DR: For example, Washington et al. as discussed by the authors investigated the prevalence and growth dynamics of the SARS-CoV-2 variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission.
Whole Genome Sequencing in the Clinical Laboratory
TL;DR: The opportunities and challenges of developing a MPS protocol for whole genome sequencing within a clinical laboratory as well as its potential applications for clinical use are discussed.
5
Abstract 4262: Analytical validation of TruSight Oncology 500, a comprehensive genomic profiling LDT for use in routine patient care
TL;DR: Analytical validation of TruSight Oncology 500, a comprehensive genomic profiling LDT for use in routine patient care, is reported, demonstrating high accuracy and precision for the variant types found in the TSO500 panel.
2